Breast

• (101-21) A Phase 1 Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors
• (114-19) A Phase 1, open label, first-in-human study of TR1801-ADC, an antibody drug conjugate (ADC), in patients with select solid tumors expressing c-Met
• (131-17) A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (IT-01)

• (155-17) 0C 17-1: Phase 1 Multi-center Study of the Safety Pharmacokinetics and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors and C-Met Dysregulation

• (167-18) A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

• (173-18) Perioperative Mindfulness Proposal

• (178-18) A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors

• (182-20) 18F-FLUORESTRADIOL (FES) PET/CT COMPARED TO STANDARD-OF-CARE IMAGING IN PATIENTS WITH BREAST CANCER (Phase 2 clinical trial, appropriate for patients with breast cancer.)

• (187-17) Trial of ZW25 in Patients With Advanced HER2-expressing Cancers

• (187-19) A Phase 1/2 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer

• (188-18) A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors

• (189-18) ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors

• (205-19) Study to Assess AFM24 in Advanced Solid Cancers

• (214-17) An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

• (221-19) Study of GNX102 in Patients With Advanced Solid Tumors

Certain clinical trials may not be listed on ClinicalTrials.gov. To learn more about these or other clinical trials, please call 949-764-5543